SCHEMBL5228664

SCHEMBL5228664

CCOC(=O)c1nn(-c2ccccc2)c2c1ccc1[nH]ncc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.52
KDM4E B2RXH2 5/20 0.52
HSD17B10 Q99714 2/20 0.52
HPGD P15428 2/20 0.52
MAPT P10636 3/20 0.49
ALOX12 P18054 2/20 0.49
ALOX15 P16050 1/20 0.49
CASP1 P29466 1/20 0.49
ADORA1 P30542 1/20 0.49
TP53 P04637 1/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
PDE4D Q08499 2/20 0.46
APP P05067 3/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232468 0.90 CCNA2 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL5229613 0.88 CCNA2 (0.57) ALDH1A1KDM4EHSD17B10MAPTALOX15
SCHEMBL5226690 0.83 MAPK1 (0.42) ALDH1A1KDM4EHPGDMAPTADORA1
SCHEMBL5229177 0.81 CCNA2 (0.50) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL5227766 0.75 CDK2 (0.52) ALDH1A1CCNA2CDK2CCNA1
SCHEMBL5230295 0.75 CCNA2 (0.53) ALDH1A1MAPTADORA1TP53CCNA2
SCHEMBL5230389 0.75 CCNA2 (0.54) ALDH1A1RAB9ACCNA2CDK2CCNA1
SCHEMBL5225569 0.74 CCNA2 (0.52) ALDH1A1CCNA2CDK2CCNA1
SCHEMBL5231857 0.72 CCNA2 (0.46) ALDH1A1KDM4EHPGDCYP3A4CYP2C9
SCHEMBL3597421 0.72 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478357-B1 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-01-31 EP claimed
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2005-08-11 US claimed
EP-1478357-B1 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-01-31 EP disclosed
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2005-08-11 US disclosed
EP-1478357-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2004-11-24 EP disclosed
WO-2003070236-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents TP53, NFATC1, MAP3K15 ALDH1A1 4396/4885KDM4E 2663/4885HSD17B10 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.